NAV

Pheniprazine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Pheniprazine
DrugBank Accession Number
DB09250
Background

Pheniprazine is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was used as an antidepressant in the 1960s. In addition, it was used for the treatment of other conditions, such as angina pectoris and schizophrenia. Pheniprazine was withdrawn by its manufacturer due to its ability to cause toxicity in the liver and its ability to cause optic neuritis.

Type
Small Molecule
Groups
Withdrawn
Structure
3D
Similar Structures
Weight
Average: 150.225
Monoisotopic: 150.115698459
Chemical Formula
C9H14N2
Synonyms
  • Pheniprazine
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

For the treatment of depression, schizophrenia, and angina pectoris.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
1,2-BenzodiazepineThe risk or severity of CNS depression can be increased when Pheniprazine is combined with 1,2-Benzodiazepine.
AbaloparatidePheniprazine may increase the orthostatic hypotensive activities of Abaloparatide.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Pheniprazine is combined with Abciximab.
AcarbosePheniprazine may increase the hypoglycemic activities of Acarbose.
AcebutololPheniprazine may increase the hypotensive activities of Acebutolol.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Pheniprazine hydrochloride5B3OM8452C66-05-7HXCTUSBYMZQLKB-UHFFFAOYSA-N
International/Other Brands
Catron / Cavodil

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenethylamines
Direct Parent
Amphetamines and derivatives
Alternative Parents
Phenylpropanes / Alkylhydrazines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Alkylhydrazine / Amphetamine or derivatives / Aromatic homomonocyclic compound / Hydrazine derivative / Hydrocarbon derivative / Organic nitrogen compound / Organonitrogen compound / Organopnictogen compound / Phenylpropane
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
37VKD7067M
CAS number
55-52-7
InChI Key
VXTWEDPZMSVFEF-UHFFFAOYSA-N
InChI
InChI=1S/C9H14N2/c1-8(11-10)7-9-5-3-2-4-6-9/h2-6,8,11H,7,10H2,1H3
IUPAC Name
(1-phenylpropan-2-yl)hydrazine
SMILES
CC(CC1=CC=CC=C1)NN

References

General References
  1. LEAR TE, BROWNE MW, GREEVES JA: A controlled trial of cavodil (pheniprazine) in depression. J Ment Sci. 1962 Nov;108:856-58. [Article]
  2. SANDLER G: Clinical evaluation of pheniprazine in angina pectoris. Br Med J. 1961 Mar 18;1(5228):792-4. [Article]
  3. WICKSTROM L, HAHN N: [beta-Phenylisoprophlhydrazine (Catran) in schizophrenia]. Nord Med. 1962 Sep 13;68:1165-7. [Article]
PubChem Compound
5929
PubChem Substance
310265153
ChemSpider
5716
ChEBI
134773
ChEMBL
CHEMBL22498
Wikipedia
Pheniprazine

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility3.75 mg/mLALOGPS
logP1.69ALOGPS
logP1.62Chemaxon
logS-1.6ALOGPS
pKa (Strongest Basic)5.65Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area38.05 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity58.68 m3·mol-1Chemaxon
Polarizability17.47 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-052f-9300000000-6261c83dd02b4e742535
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0fr6-4900000000-b19e29e1016e595981cb
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-014l-2900000000-6d03ffd409ac1753d5b5
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-00kf-9500000000-94e568ea502bc1c44884
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00kf-9600000000-f208d8e33a92614edfce
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00kf-9000000000-3d3323e133cf929a884d
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-00kf-9500000000-824911985492186a7231
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-128.46558
predicted
DeepCCS 1.0 (2019)
[M+H]+131.53111
predicted
DeepCCS 1.0 (2019)
[M+Na]+140.73256
predicted
DeepCCS 1.0 (2019)

Drug created at October 24, 2015 04:06 / Updated at February 02, 2024 22:52